摘要
替戈拉生作为一种新型的钾竞争性酸阻断剂,能够高选择性的通过抑制H+/K+ ATP酶,阻断H+-K+交换,有效减少胃酸分泌,同时能有效地克服质子泵抑制剂的不足,在治疗许多酸相关疾病中显示出良好的效果。本文对其药理学、临床应用研究进展及安全性加以总结。
As a novel potassium-competitive acid blocker, tegoprazan can highly selectively block H+-K+ exchange by inhibiting H+/K+ ATPase, effectively reduce gastric acid secretion, and at the same time can effectively overcome the deficiencies of proton pump inhibitors, showing good results in the treatment of many acid-related diseases. This paper summarises the progress of its pharmacology, clinical application research and safety.
出处
《临床医学进展》
2024年第8期117-122,共6页
Advances in Clinical Medicine
